PRM20 Comparing the predictive performance of two variants of the elixhauser comorbidity measures for all-cause in-hospital mortality in a large multi-payer u.s. Administrative database  by Fortin, Y. et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A13
rankings obtained from standard logistic regression (LR) relative to MLM mod-
eling of risk-adjusted hospital mortality rates for stroke among hospitals in the 
south. Methods: The 2012 U.S. Nationwide Inpatient Sample (NIS) was used 
to identify patients with a primary diagnosis for ischemic stroke, using ICD-9 
diagnosis criteria. Stepwise backward selection technique with logistic regres-
sion and multilevel modeling was performed to examine the variation among 
hospitals in the south by adjusting for patient-level and hospital-level risk factors. 
The analysis included hospitals with more than 30 stroke cases in the southern 
region of the U.S. The hospital IDs have been masked in order to comply with the 
NIS data user agreement. Results: There were 19,071 stroke hospitalizations in 
320 hospitals. The same rankings were observed for top performers in hospitals’ 
observed/expected ratios (O/E) by LR and MLM. However, high O/E outlier status 
differed between the two statistical methods, yielding different rankings for worst 
performance. Hospital K, L, M were ranked as the worst 3 performers in LR whereas 
K, N, L were ranked the same in MLM. O/Es of Hospital K were 4.49 (CI= 1.62-9.84) 
and 3.942 (CI= 1.42-8.64) in LR and MLM, respectively. O/E’s of Hospital L were 4.24 
(CI= 1.90-8.13) and 3.33 (CI= 0.70-9.54) in LR and MLM, respectively. LR identified 
Hospital M’s O/E ratio as 3.58 (1.47-7.26). MLM identified Hospital N’s O/E as 3.33 
(CI= 0.70-9.54). ConClusions: Although both logistic regression and multilevel 
modeling produced similar rankings for top performers, the MLM approach was 
more conservative in its O/E ratio estimates which were shrunken towards the 
overall mean. The MLM method is recommended to better statistically adjust and 
avoid false positive identification of outliers.
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objeCtives: Tools used to address confounding, such as measures of patient 
comorbidity, should preferably be validated prior to conducting health services 
and outcomes research using novel sources of administrative health data. Our 
objective was to validate and compare the predictive performance of two vari-
ants of the Elixhauser comorbidity measures for predicting all-cause, in-hospital 
mortality using Cerner Health Facts®, a large nationwide U.S. multi-payer elec-
tronic health record database. Methods: Quan et al. and the AHRQ version 3.7 
adaptations of the Elixhauser comorbidity measures were selected to estimate 
the comorbidity burden of Health Facts® inpatients, outpatients, and emergency 
care recipients aged 18 to 89 years from Jan. 2000 to Dec. 2012. Diagnoses identi-
fied one and two years preceding an index encounter were assessed in a group 
of unique patients. C-statistics obtained from forward stepwise multiple logistic 
regression fitted models and ROC curve differences were derived to compare the 
predictive performance of each variant/lookback period combination. Results: 
Of 8,128,713 patients with a mean age of 51.4 years and a male composition of 
41.6%, 76,235 (0.9%) were deceased at 1-year. Age, sex and all comorbidities were 
significantly correlated with mortality in the two Elixhauser variants irrespec-
tive of lookback period. Excellent predictive performance (c-statistic) was found 
for the Quan (c1yr= 0.874, c2yrs= 0.873) and AHRQ (c1yr= 0.871, c2yrs= 0.870) vari-
ants and both exceeded the baseline model (c= 0.803, P< .0001) limited to age and 
sex. The Quan variant performed slightly better than the AHRQ variant in both 
lookback periods. However, increasing the lookback period from 1 to 2 years did 
not improve predictive performance. ConClusions: Variants of the Elixhauser 
comorbidity measures were validated in Cerner Health Facts® and demonstrated 
excellent predictive performance for all-cause in-hospital mortality at one year. 
These results support the utility of Health Facts® as a novel and attractive source 
of data for administrative database research.
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objeCtives: Retrospective chart reviews are often used to generate real-world evi-
dence of patient outcomes. Physicians participating in these studies may be asked 
to randomly select patient charts for inclusion among all charts meeting eligibility 
criteria. Random selection is important for obtaining representative samples and 
unbiased estimates of patient outcomes. This study examined a statistical method 
for detecting non-random selection of patient charts with an application to real 
data. Methods: Example data were drawn from a recent retrospective oncology 
chart review study that estimated overall survival (OS) and progression-free survival 
(PFS) following the start of treatment. In the study, participating physicians were 
asked to provide a random sample of their eligible patients. Latent class analysis 
(LCA) was used to test whether the distribution of PFS and OS was consistent with 
random selection for all charts (a one class model) versus a mixture in which some 
physicians selected random charts and others selected non-random, convenient 
charts (models with > 1 class). The best fitting model was identified using infor-
mation criteria. Physician characteristics, PFS and OS were compared across latent 
classes. Results: In overall sample of charts, median durations of OS and PFS 
were significantly longer than published benchmarks drawn from randomized tri-
als. LCA identified evidence for two classes of physicians. One class was consistent 
with biased selection for recently seen patients who were still alive at the time 
of chart review, resulting in bias towards longer OS and PFS. The other class was 
consistent with random selection, and exhibited OS and PFS that were significantly 
closer to published benchmarks. ConClusions: In this example using data from 
a retrospective oncology chart review, LCA was helpful in identifying physicians 
who may have selected convenient but non-random patient charts. LCA warrants 
0.40), and 0.72 (0.50-0.90), respectively, but were stable over time (re-test). For data 
available in 2009, incidence of PML (cases per 100,000 patients) over two years was 
estimated at 0.22 (95% CI 0.00078–3.13) for patients initiated on efalizumab and 
1.21 (0.0052–14.81) for patients remaining on treatment. ORs versus placebo were 
1.7 (1.4–2.2) for AEs and 1.5 (0.6–5.1) for SAEs. Combination of normalized weights 
and scores yielded a safety estimate of efalizumab versus placebo in 2009 of -0.65 
(stdev 0.28) (on a scale of -1 to +1). The same approach was applied to compare 
efalizumab with three active comparators. ConClusions: The method supports 
comparative safety assessment and captures uncertainty in judgments and in data, 
allowing the inclusion of rare, disparate and newly emergent safety data in quan-
titative assessments.
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objeCtives: Utility estimates are important health outcomes for economic evalua-
tion of care and treatment interventions for patients with HIV/AIDS. We conducted 
a systematic review and meta-analysis of utility measurements to examine the 
performance of preference-based instruments, estimate health utility of patients 
with HIV/AIDS by disease stages, and investigate changes in their health utility over 
the course of antiretroviral treatment. Methods: We searched PubMed/Medline, 
Cochrane Database of Systematic Review, NHS Economic Evaluation Database and 
Web of Science for English-language peer-reviewed papers published during 2000-
2013. We selected 49 studies that used 3 direct and 6 indirect preference based 
instruments to make a total of 218 utility measurements. Random effect models 
with robust estimation of standard errors and multivariate fractional polynomial 
regression were used to obtain the pooled estimates of utility and model their 
trends. Results: Reliability of direct-preference measures tended to be lower than 
other types of measures. Utility elicited by two of the indirect preference meas-
ures - SF-6D (0.171) and EQ-5D (0.114), and that of Time-Trade off (TTO) (0.151) 
was significantly different than utility elicited by Standard Gamble (SG). Compared 
to asymptomatic HIV patients, symptomatic and AIDS patients reported a decre-
ment of 0.025 (p= 0.40) and 0.176 (p= 0.001) in utility scores, adjusting for method of 
assessment. In longitudinal studies, the pooled health utility of HIV/AIDS patients 
significantly decreased in the first 3 months of treatment, and rapidly increased 
afterwards. Magnitude of change varied depending on the method of assessment 
and length of antiretroviral treatment. ConClusions: The study provides an 
accumulation of evidence on measurement properties of health utility estimates 
that can help inform the selection of instruments for future studies. The pooled 
estimates of health utilities and their trends are useful in economic evaluation and 
policy modelling of HIV/AIDS treatment strategies.
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objeCtives: This study sought to compare and improve the methods for estimating 
input parameters to populate a decision-analytic Markov model for use in the health 
economic assessment of novel biomarkers for primary prevention of Cardiovascular 
Disease. Methods: An initial five-state Markov model is built using the FINRISK97 
cohort and follow-up for coronary and stroke events. Two different approaches to 
estimate the transition rates between health states are used. The first approach 
involves a separate analysis for each of the transitions between different health 
states each using a separate Cox Proportional Hazards model (censoring any move-
ments outside the health states of interest). In the second approach, all the transi-
tions are examined in one process using the R package ‘msm’ to maximize the 
overall likelihood expression. Results: The first approach requires considerable 
data manipulation to account for the censoring in each separate analysis; however 
convergence of results is less problematic. While msm considers the overall likeli-
hood expression, it has difficulty fitting a five-state model due to the number of 
parameters which need estimated. Two recommendations from this research for 
using msm include building the model iteratively, adding covariates one step at a 
time. For example to build the model with age plus one covariate, the baseline tran-
sition matrix and regression coefficients from the age only model are used as initial 
guesses. The second recommendation would be to use the regression coefficients 
obtained in the first approach for initial “guesses” of the coefficients in the second 
approach. ConClusions: Parameter estimation for the Markov process within 
decision-analytic Markov models can be obtained from separate sources, but we 
recommend fitting Markov models to one source of longitudinal data. The output for 
the parameter estimates varied between the approaches used, and while msm is a 
useful tool for parameter estimation, it requires reasonable initial approximations.
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objeCtives: There are conflicting results about whether using multilevel mod-
eling (MLM) produces different rankings in hospital performance compared 
to using traditional statistical techniques. We would like to compare hospital 
